Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

10 Appendix
10.3.10 Nasal delivery of 3 mg midazolam (Preparation 4 and 5)
100
Subject 1: 3mg midazolam nasal
100
Subject 3: 3mg midazolam nasal
P4
90
(Preparation 4 and 5)
90
(Preparation 4 and 5)
P5
80
80
P4
70
70
P5
60
60
50
50
40
40
30
30
20
20
10
10
0
0
-10 40 90 140 190 240 290 340 390
-10 40 90 140 190 240 290 340 390
Minuten
Midazolam serum concentration [ug/ml
100
Subject 4: 3mg midazolam nasal
100
Subject 6: 3mg midazolam nasal
90
(Preparation 4 and 5)
P4
90
(Preparation 4 and 5)
80
70
P5
80
70
P4
P5
60
60
50
50
40
40
30
30
20
20
10
10
0
0
-10 40 90 140 190 240 290 340 390
-10 40 90 140 190 240 290 340 390
Minuten
Minuten
100
100
90
90
80
80
70
70
60
60
50
50
40
40
30
30
20
20
10
10
Subject Subject 9: 3mg 9: 3mg midazolam midazolam nasal
nasal
(Preparation (Preparation 4 and 4 and 5)
5)
P4
P4
P5
P5
100
90
Subject 11: 3mg midazolam nasal
(Preparation 4 and 5)
80
P4
70
60
50
40
30
20
10
0
0
0
-10 -10 40 40 90 90 140 140 190 190 240 240 290 290 340 340 390
390
-10 40 90 140 190 240 290 340 390
Minuten
Minuten
Minuten
P5
100
90
80
Subject 13: 3mg midazolam nasal
(Preparation 4 and 5)
P4
100
90
80
Subject 14: 3mg midazolam nasal
(Preparation 4 and 5)
P4
70
P5
70
P5
60
60
50
50
40
40
30
30
20
20
10
10
0
-10 40 90 140 190 240 290 340 390
Minuten
0
-10 40 90 140 190 240 290 340 390
Minuten
Time [min]
Figure 10-5: Nasal administration of 3 mg (Preparation 4 and 5) to 8 healthy volunteers.
Katja Suter-Zimmermann Page 162 of 188 University of Basel, 2008